Cigna Group/$CI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.

Ticker

$CI
Sector

Primary listing

NYSE

Employees

72,398

Cigna Group Metrics

BasicAdvanced
$82B
16.77
$18.24
0.49
$5.82
1.97%

What the Analysts think about Cigna Group

Analyst ratings (Buy, Hold, Sell) for Cigna Group stock.

Bulls say / Bears say

Evernorth revenue rose 17% year-over-year to $57.83 billion in Q2 2025, driven by robust growth in its pharmacy benefit management and specialty pharmacy services (Reuters)
Cigna reported Q2 adjusted EPS of $7.20, surpassing the $7.15 consensus estimate, and reaffirmed its full-year guidance of at least $29.60 per share, underscoring resilient profitability (Reuters)
Total Q2 2025 revenue of $67.2 billion exceeded analysts’ projection of $62.7 billion, reflecting strong demand and execution across its health services and PBM segments (Barron's)
FTC preparing to resume its insulin pricing lawsuit against Cigna’s Express Scripts could expose the company to significant legal liabilities and reputational damage if allegations of steering patients toward higher-priced drugs are upheld (Reuters)
Arkansas Governor’s recent legislation to ban PBMs from owning pharmacies directly targets Express Scripts’ vertical integration model and, if upheld, may spur similar state-level restrictions that erode Cigna’s competitive moat (Financial Times)
CFRA warns that industry-wide medical cost pressures will persist in 2025, forecasting Cigna’s medical cost ratio to average 83.2%–84.2%, which could materially compress margins in its healthcare segment (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.

Cigna Group Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cigna Group Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept18
Cigna Group
DividendPayment
$1.51Per share
FAQs